Association between benign thyroid disease and breast cancer: a single center experience.
Benign thyroid disease
Breast cancer
Menopause
Thyroid disorders
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
17 Oct 2019
17 Oct 2019
Historique:
received:
16
04
2019
accepted:
10
09
2019
entrez:
19
10
2019
pubmed:
19
10
2019
medline:
13
3
2020
Statut:
epublish
Résumé
The relationship between breast cancer (BC) and thyroid disease (TD) is still controversial. The aim of the study was to investigate the possible coexistence of TD in patients with newly diagnosed BC and its correlation with BC clinical presentation with regard to menopausal status and stage of disease. This is a retrospective cohort study of all patients treated for primary BC between 2014 and 2016 at the Breast Unit of Trieste University Hospital. Clinical charts and reports were reviewed for coexisting thyroid disorders (i.e. hyperthyroidism, hypothyroidism, benign TD, thyroid cancer, thyroid autoimmunity) and menopausal status at the time of BC diagnosis. Biomolecular profile, stage, and grading of BC were also evaluated. A total of 786 women and 7 men were included in the study. Co-presence of TD was found in 161(20.3%) cases: of these, 151(19.4%) patients presented benign TD and 10(1.3%) patients presented thyroid carcinoma. Thyroid autoimmunity was found in 51(32%) patients. Regarding thyroid function, 88(55%) patients had hypothyroidism, 19(12%) hyperthyroidism, and 54(33%) normal thyroid function. No statistically significant correlation was found between age and TD (p = 0.16), although TD was more common in women aged ≥60 years. Women with BC diagnosed at pre-menopausal age were more likely to have thyroid autoimmune diseases (45% vs. 29%, p = 0.05). No association was detected among BC molecular profiles with either thyroid autoimmunity (p = 0.26) or altered thyroid function (p = 0.63). High-grade BC was more frequent in women with hyperthyroidism (52.9%, p = 0.04), but the grading was independent from the presence of thyroid autoimmune disease (p = 0.87). BC stage was related to both thyroid autoimmunity (p = 0.04) and thyroid function (p < 0.001), with 55.2% of women affected by benign TD presenting with stage I BC and more aggressive BCs found in hypothyroid patients. According our study results, patients with primary BC present a greater incidence of autoimmunity disorders, especially when diagnosed in the pre-menopausal setting. However, further prospective studies are required to definitively prove causality.
Sections du résumé
BACKGROUND
BACKGROUND
The relationship between breast cancer (BC) and thyroid disease (TD) is still controversial. The aim of the study was to investigate the possible coexistence of TD in patients with newly diagnosed BC and its correlation with BC clinical presentation with regard to menopausal status and stage of disease.
METHODS
METHODS
This is a retrospective cohort study of all patients treated for primary BC between 2014 and 2016 at the Breast Unit of Trieste University Hospital. Clinical charts and reports were reviewed for coexisting thyroid disorders (i.e. hyperthyroidism, hypothyroidism, benign TD, thyroid cancer, thyroid autoimmunity) and menopausal status at the time of BC diagnosis. Biomolecular profile, stage, and grading of BC were also evaluated.
RESULTS
RESULTS
A total of 786 women and 7 men were included in the study. Co-presence of TD was found in 161(20.3%) cases: of these, 151(19.4%) patients presented benign TD and 10(1.3%) patients presented thyroid carcinoma. Thyroid autoimmunity was found in 51(32%) patients. Regarding thyroid function, 88(55%) patients had hypothyroidism, 19(12%) hyperthyroidism, and 54(33%) normal thyroid function. No statistically significant correlation was found between age and TD (p = 0.16), although TD was more common in women aged ≥60 years. Women with BC diagnosed at pre-menopausal age were more likely to have thyroid autoimmune diseases (45% vs. 29%, p = 0.05). No association was detected among BC molecular profiles with either thyroid autoimmunity (p = 0.26) or altered thyroid function (p = 0.63). High-grade BC was more frequent in women with hyperthyroidism (52.9%, p = 0.04), but the grading was independent from the presence of thyroid autoimmune disease (p = 0.87). BC stage was related to both thyroid autoimmunity (p = 0.04) and thyroid function (p < 0.001), with 55.2% of women affected by benign TD presenting with stage I BC and more aggressive BCs found in hypothyroid patients.
CONCLUSIONS
CONCLUSIONS
According our study results, patients with primary BC present a greater incidence of autoimmunity disorders, especially when diagnosed in the pre-menopausal setting. However, further prospective studies are required to definitively prove causality.
Identifiants
pubmed: 31623603
doi: 10.1186/s12902-019-0426-8
pii: 10.1186/s12902-019-0426-8
pmc: PMC6798360
doi:
Substances chimiques
Biomarkers
0
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104Références
Clin Ter. 2012 Nov;163(6):e401-4
pubmed: 23306753
Breast Cancer Res Treat. 2014 Apr;144(3):683-8
pubmed: 24604093
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
J Clin Endocrinol Metab. 1996 Mar;81(3):990-4
pubmed: 8772562
J Clin Endocrinol Metab. 1998 Aug;83(8):2711-6
pubmed: 9709936
J Endocrinol Invest. 2017 Feb;40(2):179-184
pubmed: 27624298
Epidemiol Rev. 1990;12:16-28
pubmed: 2286217
Breast Cancer Res. 2003;5(5):235-8
pubmed: 12927031
Ann Med. 1997 Jun;29(3):189-91
pubmed: 9240623
Nat Med. 2000 Aug;6(8):871-8
pubmed: 10932223
Ann Oncol. 2006 Jan;17(1):60-4
pubmed: 16282247
Arch Endocrinol Metab. 2017 Jan-Feb;61(1):54-61
pubmed: 28273204
Eur J Endocrinol. 2016 Apr;174(4):409-14
pubmed: 26863886
PLoS One. 2017 Jun 2;12(6):e0179066
pubmed: 28575127
J BUON. 2009 Jul-Sep;14(3):425-8
pubmed: 19810133
Eur Thyroid J. 2017 Jul;6(4):197-207
pubmed: 28868260
Eur J Surg Oncol. 2001 Nov;27(7):626-30
pubmed: 11669589
Lancet. 1976 Oct 9;2(7989):807-8
pubmed: 61482
Eur J Cancer Clin Oncol. 1987 May;23(5):553-6
pubmed: 3653178
JAMA. 1976 Sep 6;236(10):1124-7
pubmed: 988872
Breast Cancer Res Treat. 2012 Jun;133(3):1169-77
pubmed: 22434524
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Breast Cancer Res Treat. 2015 Jan;149(1):293-301
pubmed: 25542270
Mol Clin Oncol. 2015 May;3(3):629-632
pubmed: 26137279
J Endocrinol Invest. 2011 May;34(5):349-52
pubmed: 20595798
Eur J Endocrinol. 2006 May;154(5):645-9
pubmed: 16645010